John Wolchko Net Worth

The estimated Net Worth of J Scott Wolchko is at least $23.4 Milion dollars as of 9 January 2024. Mr. Wolchko owns over 14,391 units of Fate Therapeutics Inc stock worth over $1,440,442 and over the last 11 years he sold FATE stock worth over $11,250,078. In addition, he makes $10,721,000 as President, Chief Executive Officer oraz Director at Fate Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Wolchko FATE stock SEC Form 4 insiders trading

John has made over 30 trades of the Fate Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 14,391 units of FATE stock worth $62,889 on 9 January 2024.

The largest trade he's ever made was selling 69,407 units of Fate Therapeutics Inc stock on 8 January 2021 worth over $8,074,116. On average, John trades about 19,036 units every 79 days since 2014. As of 9 January 2024 he still owns at least 371,248 units of Fate Therapeutics Inc stock.

You can see the complete history of Mr. Wolchko stock trades at the bottom of the page.

John Wolchko biography

John Scott Wolchko is the President, Chief Executive Officer, Director of Fate Therapeutics Inc. Mr. Wolchko has also served as our Chief Operating Officer since February 2013 and as our Chief Financial Officer since the commencement of our operations in September 2007. Mr. Wolchko began his career in 1994 as an investment banker with Morgan Stanley & Co., serving in the firm’s New York City and Menlo Park, California offices. As a member of the firm’s Investment Banking Health Care Group, he assisted emerging growth companies in the life sciences sector complete capital-raising and M&A transactions. Prior to joining us, from July 2001 to September 2007, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., an enterprise software company that specializes in data protection management. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont. The Board of Directors believes Mr. Wolchko’s extensive leadership, executive, managerial, business and healthcare industry experience qualifies him to serve as a member of our Board of Directors. In addition, Mr. Wolchko’s day-to-day management and intimate knowledge of our business and operations provide our Board with an in-depth understanding of the Company.

What is the salary of John Wolchko?

As the President, Chief Executive Officer oraz Director of Fate Therapeutics Inc, the total compensation of John Wolchko at Fate Therapeutics Inc is $10,721,000. There are no executives at Fate Therapeutics Inc getting paid more.

How old is John Wolchko?

John Wolchko is 49, he's been the President, Chief Executive Officer oraz Director of Fate Therapeutics Inc since 2017. There are 8 older and 8 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.

What's John Wolchko's mailing address?

J's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... oraz Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.

What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Complete history of Mr. Wolchko stock trades at Fate Therapeutics Inc

Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Wolchko,
  President, Chief Executive Officer, Director
• Bahram Valamehr,
  Chief Development Officer
• Cindy Tahl,
  General Counsel and Corporate Secretary
• Daniel Shoemaker,
  Chief Scientific Officer
• J. Scott Wolchko,
  Founder, CEO, Pres & Director
• Dr. Bahram Valamehr Ph.D.,
  Chief R&D Officer
• Cindy R. Tahl,
  Gen. Counsel & Corp. Sec.
• Karin Jooss,
  Independent Director
• Shefali Agarwal,
  Director
• William Rastetter,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• John Mendlein,
  Independent Vice Chairman of the Board
• Robert Epstein,
  Independent Director
• Michael Lee,
  Independent Director
• Edward Dulac,
  Chief Financial Officer
• Robert Hershberg,
  Director
• Renee Leck,
  IR Contact Officer
• Yu-Waye Chu,
  Vice President - Clinical Development
• Sarah Cooley,
  Senior Vice President - Clinical Translation
• Dr. Mark Plavsic D.V.M., Ph.D.,
  Chief Technical Officer
• Dr. Yu-Waye Chu M.D.,
  Sr. VP of Clinical Devel.
• Jim Beitel M.B.A.,
  Sr. VP of Corp. Devel.
• Dr. Wen Bo Wang,
  Sr. VP of Technical Operations
• Edward J. Dulac III,
  CFO & Principal Accounting Officer
• Mark J Enyedy,
  Director
• Stewart Abbot,
  Chief Development Officer
• Chris Storgard,
  Chief Medical Officer
• Amir Nashat,
  Director
• Brian T. Powl,
  Chief Commercial Officer
• J Scott Wolchko,
  President and CEO
• Group, Llc Green Jeremy Red...,
  
• Pratik S Multani,
  Chief Medical Officer
• Peter D Flynn,
  See remarks
• Christian Weyer,
  See remarks
• Venture Fund Vi Lparch Vent...,
  
• Venture Partners Vii Lpovp ...,
  
• Venture Management Co. V, L...,
  
• Robert Nelsen,
  Director
• Associates V Lpvenrock Part...,
  
• Yuan Xu,
  
• Mark Plavsic,
  Chief Technical Officer
• Neelufar Mozaffarian,